Estuary Biotherapeutics launches with $103 million to develop targeted gene therapies for kidney disease
Estuary Biotherapeutics, Inc., a biotechnology company developing genetic medicines for patients with serious kidney diseases, announced its launch with $103 million in total committed financing. The $93 million
Full article text belongs to the original publisher. Moogle News shows the headline/summary and sends you to the source.
Read full story on publisher site →